- RNA targeted therapeutics
- Gene Therapies
- Epigenetic and microRNA modulating therapies.
- Genome editing therapies.
- Others
Nucleic Acid Therapeutics Market size was valued at USD X million in 2023 and is projected to expand at a CAGR of 14.8% from 2024 - 2030. Rising investments in the healthcare sector have also fuelled research into the treatment of numerous diseases and ailments. The rising prevalence of chronic diseases in the population, combined with genetic problems, has resulted in an increase in research activities aimed at improving healthcare systems around the world. According to an article released by MDPI in February 2022, nucleic acid-based technologies, such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNAs (miRNAs), are the most promising for combating the COVID-19 virus. These treatments can decrease viral gene expression during and after transcription, giving considerable growth prospects.
Recent Developments in the Nucleic Acid Therapeutics Market
- In October 2022, EnPC (Engineered Protein Capsules), a protein-based drug delivery technology, and Neuway Pharma GmbH and Wacker had announced the start of a research collaboration to identify and produce RNA-based treatments for the treatment of central nervous system disorders.
- In August 2022, Merck & Co. and Orna Therapeutics, Inc. will create and market a new type of therapeutic RNA for the treatment of infectious and oncological diseases.
Nucleic Acid Therapeutics Market Summary
Study Period
2024 – 2030
Base Year
2023
CAGR
14.8%
Largest Market
North America
Fastest Growing Market
Asia pacific
Nucleic Acid Therapeutics Market Dynamics
The nucleic acid therapeutics market is expected to grow rapidly because of the various new medications that are currently being approved and developed. The rise of the nucleic acid therapeutics market is fuelled by the growth of the pharmaceutical and healthcare sectors, as well as the development of biological goods and DNA therapies. On the other hand, the growth of the worldwide nucleic acid treatments market is likely to be hampered by a lack of experience, technology, and high costs. Because both developed and emerging countries play an important role in the research and development of innovative medicines, the market is expected to grow in the future.
The high cost of research and development, as well as costly treatments and technologies, are some of the major impediments to business expansion. Additional factors driving worldwide market growth for nucleic acid therapeutics include faster absorption and market access, strong product demand, and a greater emphasis of pharmaceutical companies on the development of nucleic acid therapeutics.
North-America Got Significant Share
Nucleic Acid Therapeutics Market Regional Analysis
Based on regions, the Market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is projected to dominate the market because of the high frequency of chronic illnesses such as cancer and diabetes, the growing need for focused and customized therapy, and supportive government activities. More than 130 people in the United States currently have diabetes, according to the CDC National Diabetes Statistical Report, which was published in January 2022. The U.S. has dominated North American markets. The key drivers of market expansion include increased investment in R&D activities, which leads to more innovations in gene therapy, as well as the rising prevalence of target diseases.
Latin America
Europe
Asia Pacific
Middle East
North America
Nucleic Acid Therapeutics Market Segmentation
By Technology
By Application
- Autoimmune Disorders
- Genetic Disorders
- Infectious Diseases
- Cancer
- Others
By End User
- Hospitals & Clinics
- Academic & Research Institutes
- Others
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The Nucleic Acid Therapeutics Market is expected to grow at a CAGR of 14.8%.
Companies' growing emphasis on collaborations, partnerships, new product launches, and other initiatives enhances the availability of novel therapeutic pharmaceuticals in the market, thereby driving market growth.
The advancement of molecular technologies and continual omics-based research have been trending, resulting in significant investments by numerous companies.
Market research is segmented based on technology, application, end user and region.
North America is estimated to dominate with the highest CAGR over the forecast period.
Key Features of the Reports
- The report provides granular level information about the Market size, regional Market share, historic Market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key Market developments, and key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the Market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the Market.
- The report provides a plethora of information about Market entry strategies, regulatory framework, and reimbursement scenarios.
| 1. Executive Summary |
| 2. Global Nucleic Acid Therapeutics Market Introduction |
| 2.1.Global Nucleic Acid Therapeutics Market - Taxonomy |
| 2.2.Global Nucleic Acid Therapeutics Market - Definitions |
| 2.2.1.Technology |
| 2.2.2.Application |
| 2.2.3. End User |
| 2.2.4.Region |
| 3. Global Nucleic Acid Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Nucleic Acid Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Nucleic Acid Therapeutics Market By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. RNA targeted therapeutics |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Gene Therapies |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Epigenetic and microRNA modulating therapies. |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Genome editing therapies. |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Nucleic Acid Therapeutics Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Autoimmune Disorders |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Genetic Disorders |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Infectious Diseases |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Cancer |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Nucleic Acid Therapeutics Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals & Clinics |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Academic & Research Institutes |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Nucleic Acid Therapeutics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Nucleic Acid Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.RNA targeted therapeutics |
| 9.1.2.Gene Therapies |
| 9.1.3.Epigenetic and microRNA modulating therapies. |
| 9.1.4.Genome editing therapies. |
| 9.1.5.Others |
| 9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Autoimmune Disorders |
| 9.2.2.Genetic Disorders |
| 9.2.3.Infectious Diseases |
| 9.2.4.Cancer |
| 9.2.5.Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals & Clinics |
| 9.3.2.Academic & Research Institutes |
| 9.3.3.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Nucleic Acid Therapeutics Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.RNA targeted therapeutics |
| 10.1.2.Gene Therapies |
| 10.1.3.Epigenetic and microRNA modulating therapies. |
| 10.1.4.Genome editing therapies. |
| 10.1.5.Others |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Autoimmune Disorders |
| 10.2.2.Genetic Disorders |
| 10.2.3.Infectious Diseases |
| 10.2.4.Cancer |
| 10.2.5.Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals & Clinics |
| 10.3.2.Academic & Research Institutes |
| 10.3.3.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Nucleic Acid Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.RNA targeted therapeutics |
| 11.1.2.Gene Therapies |
| 11.1.3.Epigenetic and microRNA modulating therapies. |
| 11.1.4.Genome editing therapies. |
| 11.1.5.Others |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Autoimmune Disorders |
| 11.2.2.Genetic Disorders |
| 11.2.3.Infectious Diseases |
| 11.2.4.Cancer |
| 11.2.5.Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals & Clinics |
| 11.3.2.Academic & Research Institutes |
| 11.3.3.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Nucleic Acid Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.RNA targeted therapeutics |
| 12.1.2.Gene Therapies |
| 12.1.3.Epigenetic and microRNA modulating therapies. |
| 12.1.4.Genome editing therapies. |
| 12.1.5.Others |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Autoimmune Disorders |
| 12.2.2.Genetic Disorders |
| 12.2.3.Infectious Diseases |
| 12.2.4.Cancer |
| 12.2.5.Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals & Clinics |
| 12.3.2.Academic & Research Institutes |
| 12.3.3.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Nucleic Acid Therapeutics Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.RNA targeted therapeutics |
| 13.1.2.Gene Therapies |
| 13.1.3.Epigenetic and microRNA modulating therapies. |
| 13.1.4.Genome editing therapies. |
| 13.1.5.Others |
| 13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Autoimmune Disorders |
| 13.2.2.Genetic Disorders |
| 13.2.3.Infectious Diseases |
| 13.2.4.Cancer |
| 13.2.5.Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals & Clinics |
| 13.3.2.Academic & Research Institutes |
| 13.3.3.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Novartis |
| 14.2.2.Moderna Inc |
| 14.2.3.BioNTech |
| 14.2.4.Arrowhead Pharmaceuticals |
| 14.2.5.Merck |
| 14.2.6.Thermo Fischer Scientific |
| 14.2.7.Sanofi |
| 14.2.8.Alnylam Pharmaceuticals |
| 14.2.9.Sarepta Therapeutics |
| 14.2.10.Qiagen |
| 14.2.11.Imugene |
| 14.2.12.Copernicus Therapeutics Inc |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Novartis
- Moderna Inc
- BioNTech
- Arrowhead Pharmaceuticals
- Merck
- Thermo Fischer Scientific
- Sanofi
- Alnylam Pharmaceuticals
- Sarepta Therapeutics
- Qiagen
- Imugene
- Copernicus Therapeutics Inc